

U.S. Patent Application 09/446,808

Appendix D

Abstract of the Disclosure

[The present application relates to a] A process for identifying [cancerogenic] carcinogenic agents, wherein the potentially [cancerogenic] carcinogenic agents are administered to a mammal with a DNA repair disturbance caused by inhibiting [the] poly (ADP ribose) polymerase.



Appendix E

Amended Claims (marked-up copy)

2. (Twice Amended) The method according to claim 10, wherein the inhibition of the poly(ADP ribose) polymerase is caused by the expression of a dominant negative transgenic poly(ADP ribose) polymerase.

3. (Amended) The method according to claim [10 or 2] 2 or 10, wherein the inhibition of the poly(ADP ribose) polymerase [is made] has been effected by a transgenic operation.

4. (Twice Amended) The method according to any one of claims [10 to 3] 2, 3 and 10, wherein the mammal used is a transgenic mouse.

5. (Twice Amended) The method according to any one of the claims [10 to 4] 2, 3, 4 and 10, wherein the potentially [cancerogenic] carcinogenic agents are administered by topical application.

6. (Twice Amended) The process according to any one of claims [10 to 5] 2, 3, 4, 5 and 10, wherein the mammal expresses transgenically the DNA construct shown in [figure] Figure 1.

10. (Amended) A method for identifying [cancerogenic] carcinogenic agents, said method comprising [the step of] (i) administering one or more potentially [carcenogenic] carcinogenic agents to a transgenic mammal having a transgenically modified genome comprising a DNA repair disturbance caused by a transgene of the transgenic mammal inhibiting [the] poly(ADP ribose) polymerase, and (ii) comparing said transgenic mammal administered one or more potential carcinogenic agents, with a transgenic mammal not administered said one or more potential carcinogenic agents, wherein

development of tumor in the transgenic mammal administered said one or more potential carcinogenic agents, indicates that a potential carcinogenic agent is a carcinogenic agent.

11. (Amended) A transgenic mammal comprising a genome comprising a DNA repair disturbance caused by a transgene of the transgenic mammal inhibiting [the] poly(ADP ribose) polymerase.

13. (Amended) The transgenic mammal of claim 11, wherein the inhibition of the poly(ADP ribose) polymerase is caused by expression of a dominant negative transgenic poly(ADP ribose) polymérase.

14. (Amended) The transgenic mammal of claim 11 wherein the inhibition of the poly (ADP ribose) polymerase [is made] has been effected by a transgenic operation.

16. (Amended) A method of identifying carcinogenic agents, comprising (i) administering one or more potential carcinogenic agents to a transgenic mammal having a genome comprising a DNA repair disturbance caused by inhibiting the poly (ADP ribose) polymerase, wherein said mammal is selected from the group consisting of [(i) mammals transiently expressing the dominant negative poly(ADP ribose) polymerase, and (ii)] transgenic mammals having a genome wherein the expression of poly (ADP ribose) polymerase is altered by an inserted gene encoding a dominant negative poly(ADP ribose) polymerase, and (ii) comparing said transgenic mammal administered one or more potential carcinogenic agents, with a transgenic mammal not administered said one or more potential carcinogenic agents, wherein development of tumor in the transgenic mammal administered said one or more potential carcinogenic agents, indicates that a potential carcinogenic agent is a carcinogenic agent.